Table 1 Risk management procedures over the 12 months from genetic testing according to age (⩾50 or <50 years) and carrier status (percentage of women)

From: Psychosocial impact of breast/ovarian (BRCA 1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort

 

Carrier (<50)

Carrier (⩾50)

Noncarrier (<50)

Noncarrier (⩾50)

Mammogram

75

100

24

41

CBE

65

100

26

12

Tamoxifen

2

20

1

6

BRMx

28

0

0

0

Ov US

61

40

5

12

BROx

32

40

2

2

Breast biopsy

3

20

4

5

Ovarian biopsy

7

0

0

2

BrSE

96

100

95

88

Back to article page